Welcome to our dedicated page for Xilio Therapeutics news (Ticker: XLO), a resource for investors and traders seeking the latest updates and insights on Xilio Therapeutics stock.
Xilio Therapeutics, Inc. (Nasdaq: XLO) is a biopharmaceutical company based in Waltham, Massachusetts, dedicated to pioneering tumor-activated immuno-oncology (I-O) therapies aimed at significantly improving outcomes for cancer patients. The company's name, Xilio, is derived from the Latin term 'ex nihilo,' meaning creation or big bang, symbolizing its innovative approach.
Xilio leverages its proprietary platform to develop a pipeline of novel, tumor-activated clinical and preclinical I-O molecules. These include engineered antibodies, cytokines, and chemokines, all designed to localize anti-tumor activity within the tumor microenvironment, thus optimizing the therapeutic index and minimizing systemic side effects.
Key Products and Developments:
- XTX202: An investigational tumor-activated, engineered IL-2 molecule designed to stimulate CD8+ effector T cells and natural killer (NK) cells without stimulating regulatory T cells. Recent Phase 1/2 data showed a 50% disease control rate at higher doses, and it is currently being evaluated in a Phase 2 trial for melanoma and renal cell carcinoma.
- XTX101: A tumor-activated, Fc-enhanced anti-CTLA-4 monoclonal antibody designed to block CTLA-4 and deplete regulatory T cells within the tumor microenvironment. It is being evaluated in combination with atezolizumab in a Phase 1/2 clinical trial for advanced solid tumors.
- XTX301: An engineered IL-12 molecule designed to boost anti-tumor immunity and convert 'cold' tumors into 'hot' ones. XTX301 is in a Phase 1 clinical trial, and Xilio has recently entered into an exclusive license agreement with Gilead Sciences for its development.
Recent Achievements:
- XTX202 Phase 1 monotherapy dose-escalation success at a dose level of 4.0 mg/kg, with plans to explore combination therapy opportunities.
- The company announced a strategic partnership with Gilead Sciences to accelerate the development of XTX301.
- Financial results indicate that Xilio's existing cash and cash equivalents can fund operations into the second quarter of 2025, bolstered by recent private placements and upfront payments from strategic partnerships.
For more detailed information on Xilio Therapeutics and its pipeline of tumor-activated I-O therapies, visit www.xiliotx.com.
Xilio Therapeutics (Nasdaq: XLO) announced the grant of a non-qualified stock option for 55,000 shares to Kevin Brennan, the newly appointed Senior Vice President of Finance and Accounting, effective April 1, 2023. This stock option has an exercise price of $3.17 per share, matching the closing price on March 31, 2023, and will vest in increments over four years. This action is in accordance with Nasdaq Listing Rule 5635(c)(4) and aims to incentivize Mr. Brennan's role in the company. Xilio is focused on developing tumor-activated immuno-oncology therapies to improve treatment outcomes for cancer patients.
Xilio Therapeutics, Inc. (Nasdaq: XLO) reported progress in its clinical pipeline and financial results for 2022. The company ended 2022 with $120.4 million in cash, expected to fund operations into Q2 2024. XTX202, a tumor-activated IL-2, showed promising early results in a Phase 1 trial, with plans to initiate a Phase 2 trial in April 2023. XTX301 and XTX101 are also in development, with preliminary data anticipated in 2023. However, net losses increased to $88.2 million for the year, up from $75.8 million in 2021, driven by R&D expenses, which grew to $59.2 million.
Xilio Therapeutics, a clinical-stage biotechnology company focused on tumor-activated immuno-oncology therapies, announced its participation in two investor conferences. The Cowen 43rd Annual Healthcare Conference will take place on March 6, 2023, at 9:10 a.m. ET, while the Oppenheimer 33rd Annual Healthcare Conference is scheduled for March 13, 2023, with a virtual presentation at 4:00 p.m. ET. Investors can access live webcasts on the Xilio Therapeutics website, with replays available for 30 days post-event. The company utilizes a proprietary platform to develop therapies aimed at improving cancer treatment outcomes without systemic side effects.
Xilio Therapeutics, a biotechnology firm specializing in immuno-oncology therapies, announced that CEO René Russo will speak at Citi’s 2023 Virtual Oncology Leadership Summit on February 23, 2023, at 9:00 a.m. ET. The live presentation will be available on the company's website, with a replay accessible for 30 days post-event. Xilio is focused on developing tumor-activated therapies aimed at improving cancer treatment outcomes while minimizing side effects. Their innovative approach utilizes proprietary technology to target anti-tumor activity specifically within the tumor microenvironment, with multiple programs currently in clinical and preclinical stages.
FAQ
What is the current stock price of Xilio Therapeutics (XLO)?
What is the market cap of Xilio Therapeutics (XLO)?
What is Xilio Therapeutics, Inc.?
What does the name Xilio mean?
What are the key products developed by Xilio?
What is the focus of Xilio's technology platform?
What recent achievements has Xilio reported?
What is XTX202?
What is XTX101?
What is XTX301?
How can I learn more about Xilio Therapeutics?
What are the financial prospects of Xilio Therapeutics?
